Astrazeneca Pharma India Ltd. (ASTRAZEN) Share Price Hits Fresh 52-Week Low

Astrazeneca Pharma India Ltd. at Rs 6,870, down 0.88% today, hit a fresh 52-week low of Rs 6,835.6; market capitalisation stands at Rs 17,327 crore.

Astrazeneca Pharma India Ltd. Share Price fell to Rs 6,870 on 07 September 2026, down 0.88% from the previous close of Rs 6,930.8, after touching a fresh 52-week low of Rs 6,835.6. With a market capitalisation of Rs 17,327 crore, the stock is drawing attention in Astrazeneca Pharma India Ltd. Stock News because a one-year low often signals a meaningful change in market positioning even when the supplied data does not establish a company-specific catalyst.

Today’s move places the stock among Stocks in News and also among Stocks at 52 Week Low in the Indian Stock Market. The verified data shows weak near-term price action, rich valuation multiples versus the Pharmaceuticals & Drugs benchmark, and profitability ratios that remain stronger than industry medians. That combination is why Astrazeneca Pharma India Ltd. Share Price Today is trending: the market is marking the stock lower, but the company still screens as a relatively high-return business on ROE and ROCE. For investors tracking Market News on Univest, the next points to monitor are whether the stock stabilises around this 52-week trough and how valuation, profitability and peer positioning continue to compare.

Astrazeneca Pharma India Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 6,870
Previous Close	Rs 6,930.8
Today's Move	Rs -60.8 (-0.88%)
Open	Rs 6,917
High	Rs 6,964.6
Low	Rs 6,835.6
Turnover	Rs 0.24 crore
Market Capitalisation	Rs 17,327 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,870 versus the previous close of Rs 6,930.8, a fall of 0.88%. The stock opened at Rs 6,917, reached a high of Rs 6,964.6, touched a low of Rs 6,835.6.

Astrazeneca Pharma India Ltd. Share Price Today weakened in a clearly negative session, with the stock opening at Rs 6,917, rising to an intraday high of Rs 6,964.6, and then slipping to Rs 6,835.6, which is also the fresh 52-week low. It later traded at Rs 6,870, leaving the stock down Rs 60.8 on the day, or 0.88%, against the previous close of Rs 6,930.8. Turnover stood at Rs 0.24 crore, while Market Capitalisation remained at Rs 17,327 crore.

The intraday range shows that the Astrazeneca Pharma India Ltd. Share Price could not hold early levels and spent the session closer to the day’s low than the day’s high. In Share Market Today terms, that keeps the stock relevant in Top Losers Today style screens tied to weak Price Action and Selling Pressure. The supplied numbers confirm the price event, but they do not establish a company-specific reason for why Astrazeneca Pharma India Ltd. Share News is soft today.

Univest also notes that the stock is trading below its 50-day moving average of Rs 7,544.41 and below its 200-day moving average of Rs 8,235.4, while the 14-day RSI stands at 21.48. That places the current move in a weak momentum zone and adds context before looking at valuation and company financial quality.

Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,327 crore
P/E Ratio	102.15x
P/B Ratio	19.16x
ROE	23.02%
ROCE	31.24%
EPS	Rs 67.85
Book Value Per Share	Rs 361.68
Dividend Yield	0.52%

Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 102.15x, P/B 19.16x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.

Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 17327 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 102.15x, P/B at 19.16x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.52%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.47x, median ROE of 11.78%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	102.15x
Benchmark Median P/E	32.47x
Benchmark Average P/E	48.47x
Benchmark P/E Range	3.2x to 659.73x
Company P/B Ratio	19.16x
Benchmark Median P/B	2.89x
Company ROE	23.02%
Benchmark Median ROE	11.78%
Company ROCE	31.24%
Benchmark Median ROCE	13.63%
Company Market Capitalisation	Rs 17,327 crore
Benchmark Median Market Cap	Rs 673.68 crore

Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.15x, which is above the benchmark median of 32.47x, a difference of +214.6%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.78%, a difference of +95.42%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.63%, a difference of +129.2%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Suven Pharmaceuticals Ltd.	COHANCE	17,467.48	164.43	4.54	4.02	6.12
Glenmark Life Sciences Ltd.	ALIVUS	16,781.63	27.83	4.82	18.41	24.61
Eris Lifesciences Ltd.	ERIS	18,390	28.56	4.56	19.23	14.47
Shilpa Medicare Ltd.	SHILPAMED	18,872.67	63.48	7.03	9.82	11.43
Alembic Pharmaceuticals Ltd.	APLLTD	15,878.37	22.9	2.72	12.35	11.74

Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 102.15x compared with the displayed peer median of 28.56x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 17,327 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching Astrazeneca Pharma India Ltd.

• The stock hit a fresh 52-week low of Rs 6,835.6 and traded at Rs 6,870, down 0.88% for the day.
• Price action stayed below the 50 DMA of Rs 7,544.41 and 200 DMA of Rs 8,235.4, while RSI at 21.48 indicates weak momentum.
• Valuation remains elevated at 102.15 times earnings and 19.16 times book value.
• Profitability is stronger than many industry benchmarks, with ROE of 23.02% and ROCE of 31.24%.
• The stock sits in a large Rs 17,327 crore market-cap bracket within Healthcare, making it relevant in Stock Updates and peer screens.

About Astrazeneca Pharma India Ltd.

Astrazeneca Pharma India Ltd. is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. In market classification terms, it is a mid-to-large listed pharmaceutical company with a face value of Rs 2 per share and a market capitalisation of Rs 17,327 crore. The company is tracked on both NSE and BSE, and its current market position places it among larger names relative to the median company in its industry set.

Based on the supplied company financials and indicator history, Astrazeneca Pharma India Ltd. is a profitable pharmaceuticals business with recurring revenue and net profit generation, although quarterly earnings have shown variation. That is why Astrazeneca Pharma India Ltd. Company News and Astrazeneca Pharma India Ltd. Earnings updates tend to matter for investors evaluating how valuation premiums align with operating performance in the Healthcare space.

Track Astrazeneca Pharma India Ltd. Share Price on Univest

Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.

On Univest, investors can track Astrazeneca Pharma India Ltd. Share Price Live with daily price action, 52-week levels, market capitalisation, valuation ratios, profitability indicators and peer comparison in one place. Univest also helps users follow Astrazeneca Pharma India Ltd. Share Price Update trends, Astrazeneca Pharma India Ltd. Fundamental Analysis, key technical markers, and broader sector context without relying on fragmented market sources.

For readers following Astrazeneca Pharma India Ltd. Stock News, Univest keeps the stock on watchlists that bring together Share Price, Market Cap, technical levels and industry comparisons in a single research flow.

Frequently Asked Questions

Why is Astrazeneca Pharma India Ltd. Share Price falling today?

Ans. The supplied data confirms Astrazeneca Pharma India Ltd. Share Price fell 0.88% to Rs 6,870 after touching Rs 6,835.6, a fresh 52-week low. However, the verified dataset does not establish any company-specific catalyst for today’s decline.

What is the fresh 52-week low for Astrazeneca Pharma India Ltd.?

Ans. The fresh 52-week low for Astrazeneca Pharma India Ltd. is Rs 6,835.6. The stock later traded at Rs 6,870 on the day, compared with the previous close of Rs 6,930.8, keeping it near the yearly low.

What does today’s price action show for Astrazeneca Pharma India Ltd. Share Price Today?

Ans. The stock opened at Rs 6,917, moved up to Rs 6,964.6, and slipped to Rs 6,835.6 before trading at Rs 6,870. That intraday pattern shows weakness, with the stock ending closer to the session low than high.

How expensive is Astrazeneca Pharma India Ltd. compared with its industry?

Ans. Astrazeneca Pharma India Ltd. trades at a P/E of 102.15 versus the same-industry median of 32.47 and average of 48.47. Its P/B of 19.16 also stands above the industry median of 2.89 and average of 4.27.

Are Astrazeneca Pharma India Ltd. fundamentals weak or strong?

Ans. Profitability metrics remain strong in the supplied data, with ROE at 23.02% and ROCE at 31.24%. However, valuation is demanding at 102.15 times earnings and 19.16 times book value, which keeps the stock under closer scrutiny.

What are the key financial metrics investors should watch?

Ans. The main supplied metrics are market capitalisation of Rs 17,327 crore, EPS of Rs 67.85, book value of Rs 361.68, dividend yield of 0.52, ROE of 23.02% and ROCE of 31.24%.

How does Astrazeneca Pharma India Ltd. compare with peers?

Ans. Astrazeneca Pharma India Ltd. has a higher P/E than Glenmark Life Sciences, Eris Lifesciences and Alembic Pharmaceuticals, but its ROE of 23.02% and ROCE of 31.24% are stronger than all five supplied peer companies.

What sector does Astrazeneca Pharma India Ltd. operate in?

Ans. Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The same-industry benchmark used in this analysis covers 203 companies, giving context for its valuation and profitability comparisons.

Where can investors track Astrazeneca Pharma India Ltd. Share Price updates?

Ans. Investors can track Astrazeneca Pharma India Ltd. Share Price on Univest for live price updates, 52-week levels, valuation ratios, technical markers, peer comparison and broader sector context. That makes ongoing monitoring more structured and data-driven.